A61K 31/4152
Having oxo groups directly attached to the heterocyclic ring
Official title: having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61K31/4152 (Having oxo groups directly attached to the heterocyclic ring) appears on 219 US grants and 484 published applications in this corpus.
Search patents in A61K- Granted patents
- 219
- Published applications
- 484
- Assignees
- 242
- Inventors
- 946
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 4 | 0 |
| 2001 | 2 | 0 |
| 2002 | 3 | 3 |
| 2003 | 4 | 13 |
| 2004 | 3 | 15 |
| 2005 | 3 | 5 |
| 2006 | 3 | 13 |
| 2007 | 5 | 16 |
| 2008 | 4 | 16 |
| 2009 | 6 | 10 |
| 2010 | 9 | 18 |
| 2011 | 15 | 26 |
| 2012 | 4 | 20 |
| 2013 | 5 | 12 |
| 2014 | 15 | 27 |
| 2015 | 12 | 27 |
| 2016 | 12 | 27 |
| 2017 | 6 | 18 |
| 2018 | 11 | 21 |
| 2019 | 7 | 20 |
| 2020 | 11 | 23 |
| 2021 | 13 | 25 |
| 2022 | 9 | 39 |
| 2023 | 8 | 22 |
| 2024 | 14 | 31 |
| 2025 | 15 | 21 |
| 2026 | 10 | 16 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Stable pharmaceutical compositions of edaravone and dextrocamphol6 Oct 2026US 12,751,941 B2Jiangsu Simcere Pharmaceutical Co., Ltd.
- Use of composition containing cilostazol in cerebrovascular diseases29 Sep 2026US 12,746,234 B2Neurodawn Pharmaceutical Co., Ltd.
- Oral formulations of Edaravone and method of manufacturing thereof28 Jul 2026US 12,691,099 B2Bdr Pharmaceuticals International Private Limited
- Compositions and methods for preventing and/or treating filarial disease9 Jun 2026US 12,648,929 B2The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Use of composition in treatment of cerebral stroke19 May 2026US 12,629,353 B2Jiangsu Simcere Pharmaceutical Co., Ltd.
- Edaravone suspension for oral administration13 Aug 2026US 2026/0232635 A1Shionogi & Co., Ltd.
- Stable edaravone liquid formulations and method of its use9 Jul 2026US 2026/0191777 A1
- Application of composition containing edaravone and dexborneol in improving or treating cognitive impairment11 Jun 2026US 2026/0158002 A1Neurodawn Pharmaceutical Co., Ltd.
- Use of quinolinone derivative in treatment of immune thrombocytopenia11 Jun 2026US 2026/0158028 A1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Pharmaceutical composition for oral administration of edaravone and method of administering same28 May 2026US 2026/0144775 A1K.K. Bcj-94
Most cited
By later US patents
- Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs44US 6,368,618 B1University of Georgia Research Foundation, Inc. · 2002
- Method for treating proliferative disorders with HSP90 inhibitors44US 8,034,834 B2Synta Pharmaceuticals Corp. · 2011
- Pyrazole compounds43US 6,214,813 B1Kinetek Pharmaceuticals, Inc. · 2001
- Pleasant-tasting aqueous liquid composition of a bitter-tasting drug35US 5,763,449 AAscent Pediatrics, Inc. · 1998
- Methods and compounds for inhibiting amyloid deposits32US 6,562,836 B1Queen's University of Kingston · 2003